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Mouse PDCD1 
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PDCD1 gene disruption on tumour-specific CD8+ T cells presents
important advantageous features over the current treatment, PD-1
antibodies:
• Increase in specificity: since only anti-tumour - effector T cells will
undergo such disruption, thus preventing unspecific reactions towards
healthy tissues.
• Long-term therapy: once modified T-cells are reinfused back to the
patient, in secondary organs they may differentiate into memory T
cells, long-lived cells that give an enhanced response to antigens,
thereby yielding protection from subsequent challenges by the same
type of tumour.
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Programmed death-1 (PD-1) pathway is one of the most critical checkpoint pathways responsible
for mediating tumour-induced immune suppression, normally involved in promoting tolerance and
preventing tissue damage in settings of chronic inflammation. Many human solid tumours express PD
ligand 1 (PDL1), and this is often associated with a worse prognosis. Tumour-infiltrating lymphocytes
from patients with cancer typically express PD-1 and have impaired anti-tumour functionality.
To date, several studies have revealed that the blockade of PD-1/PD-L1 pathway shows remarkable
anti-tumour responses in patients with advanced melanoma and lung cancer with durable clinical
responses. However, the long-term systemic administration of the blocking antibody carries the risk of
breaking immune tolerance and, thus, causing immune attack.
To overcome the above shortcoming, the aim of this project is to propose a proof-of-concept in a lung
squamous cell carcinoma mouse model to enhance the immune system disrupting PDCD1 gene in
autologous mouse CD8+ T-cells by CRISPR/Cas9 system, thereby reaching a more specific and long-
term therapy.
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Figure: Proof-of-concept of a CRISPR-Cas9-based therapeutic
strategy against cancer. In some tumours, constitutive oncogenic signalling can
upregulate PDL1 expression on all tumour cells (innate immune resistance); whereas in
other tumours, PD-L1 is not constitutively expressed, but rather it is induced in response to
inflammatory signals that are produced by an active anti-tumour immune response
(adaptive immune resistance). In this strategy, peripheral blood lymphocytes are collected
from brachial vessels at the axillary region of mouse and isolated through a Ficoll-hypaque
gradient. Afterwards, they are analysed for reactivity against predicted tumour epitopes
(neoantigens obtained from whole-exome sequencing of tumour cells from the mouse)
presented by mouse APCs. T cells expressing the activation marker are then purified using
flow cytometry, cultured and knocked-out by CRISPR/Cas9 system in the laboratory (PD-1
knockout). Finally, modified T-cells are expanded ex vivo in presence of IL-2 and re-infused
back into the mouse, followed by IL-2 administration. Blocking the PD-1/PD-L1 pathway by
PDCD1 disruption would suppress cancer cell survival and enhance the anti-tumour
responses of T cells, leading to tumour regression and rejection. PBMCs: Peripheral Blood
Monoclonal Cells; APCs: Antigen-presenting cells.
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5’..GTCCCAGCAACCAGAC:::::::::::::::::::::::::::::::::::::::::::TCCAGGATGCCCGCTT..3’
3’..CAGGGTCGTTGGTCTG:::::::::::::::::::::::::::::::::::::::::::AGGTCCTACGGGCGAA..5’
5’..GTCCCAGCAACCAGAC:::::::::::::GATCACCT::::::::::::::::::::::TCCAGGATGCCCGCTT..3’
3’..CAGGGTCGTTGGTCTG:::::::::::::CTAGTGGA::::::::::::::::::::::AGGTCCTACGGGCGAA..5’
sgRNA2
3’..CAGGGTCGTTGGTCTGACTTTTTGTCCGGCGGAAGACATTACCAAACTCGGTTGGGCAGGTCCTACGGGCGAA..5’
PAM sgRNA1 TGGTTTGAGCCAACCCGTCC
5’..GTCCCAGCAACCAGACTGAAAAACAGGCCGCCTTCTGTAATGGTTTGAGCCAACCCGTCCAGGATGCCCGCTT..3’
PAMCTGACTTTTTGTCCGGCGGA
